# Stephane Verdood

> Stephane Verdood is a Series A investor at Vesalius Biocapital Partners backing Health Care. See 8 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Vesalius Biocapital Partners](https://shizune.co/investors/profile/vesalius-biocapital-partners)
- Location: Strassen, Luxembourg
- Total investments: 8
- Last investment: Mar 2022
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/stephane-verdood-314a2a46

Stephane Verdood is a Series A investor at Vesalius Biocapital Partners in Strassen focused on Health Care and Biotechnology. Stephane Verdood is based out of Antwerp, Antwerpen and is the Managing Partner of Vesalius Biocapital Partners. Stephane previously worked at Arthur Andersen as a European Board of Partners. Stephane Verdood attended the Catholic University of Leuven.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 4 | 50% |
| Biotechnology | 3 | 38% |
| Pharmaceutical | 3 | 38% |
| Medical | 1 | 13% |
| Biometrics | 1 | 13% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 38% |
| Series B | 1 | 13% |
| Series C | 1 | 13% |
| Funding Round | 1 | 13% |
| Post-IPO Equity | 1 | 13% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| The Netherlands | 2 | 25% |
| Belgium | 1 | 13% |
| Finland | 1 | 13% |
| Switzerland | 1 | 13% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Scenic Biotech | Scenic Biotech is a developer of a genomics and immunotherapy technologies created to unlock genetic suppressors as a new class of drug targets.The company's immunotherapy technologies tackle diseases on the genetic level and focuses on disease suppressing genes., it uses genomics to develop innovative therapies for patients affected by severediseases. | $31M | Series A | Mar 09, 2022 |  |
| Rejuvenate Biomed | Rejuvenate Biomed is a biomedical company researching the biology of aging & applying this knowledge to identify safe and well tolerated drugs to maintain and restore our natural cell resilience capacity improving the respons to age-related diseases. | $18.1M | Series B | Oct 12, 2021 |  |
| Rejuvenate Biomed | Rejuvenate Biomed is a biomedical company researching the biology of aging & applying this knowledge to identify safe and well tolerated drugs to maintain and restore our natural cell resilience capacity improving the respons to age-related diseases. | $3.9M | Series A | Mar 02, 2021 |  |
| Forendo Pharma | Forendo Pharma is a developer of novel drugs intended for the treatment of urological and other endocrinological diseases. The company's drugs are competent in tissue-specific hormone mechanisms for the treatment of broader gynecological conditions and Fispemifene, a novel SERM, enabling medical companies to improve the treatment of maleurological conditions and giving new opportunities to unmet needs in women's and men's health. | $4.2M |  | Sep 05, 2018 |  |
| Genkyotex | Genkyotex is dedicated to the development of innovative drugs which block enzymes that produce oxygen radicals. Such novel drugs will allow the treatment of oxygen-radical mediated acute and chronic diseases, with improved specificity, safety, and efficacy over existing antioxidants therapy, giving them a significant competitive advantage.Genkyotex targets its technology initially to the therapeutic areas of cardiovascular, metabolic and neurodegenerative diseases. | $22.7M | Post-IPO Equity | Jan 07, 2015 |  |
| FF Pharma | FF Pharma, a biopharmaceutical company, develops anti-CD40 monoclonal antibody therapy for the treatment of chronic inflammatory diseases like primary biliary cirrhosis and Crohn’s disease. The functions of CD40 in immune regulation suggest that the CD40 pathway may play a role in diseases in which anomalous immune responses, e.g. autoantibodyproduction or chronic inflammation, are a feature. | $4.2M | Series A | Jan 23, 2013 |  |
| Genkyotex | Genkyotex is dedicated to the development of innovative drugs which block enzymes that produce oxygen radicals. Such novel drugs will allow the treatment of oxygen-radical mediated acute and chronic diseases, with improved specificity, safety, and efficacy over existing antioxidants therapy, giving them a significant competitive advantage.Genkyotex targets its technology initially to the therapeutic areas of cardiovascular, metabolic and neurodegenerative diseases. | $28.3M | Series C | Jul 09, 2012 |  |
| Genkyotex | Genkyotex is dedicated to the development of innovative drugs which block enzymes that produce oxygen radicals. Such novel drugs will allow the treatment of oxygen-radical mediated acute and chronic diseases, with improved specificity, safety, and efficacy over existing antioxidants therapy, giving them a significant competitive advantage.Genkyotex targets its technology initially to the therapeutic areas of cardiovascular, metabolic and neurodegenerative diseases. | $20.4M | Series C | May 24, 2011 |  |

8 of 8 investments shown.

## Co-investors
- [BioMedPartners](https://shizune.co/investors/profile/biomedpartners) — VC Fund, 3 deals together
- [Eclosion SA](https://shizune.co/investors/profile/eclosion-sa) — VC Fund, 3 deals together
- [Andera Partners](https://shizune.co/investors/profile/edmond-de-rothschild-investment-partners) — VC Fund, 3 deals together
- [MP Healthcare Venture Management](https://shizune.co/investors/profile/mp-healthcare-venture-management-inc) — VC Fund, 2 deals together
- [Centenara Labs](https://shizune.co/investors/profile/rejuveron-life-sciences) — VC Fund, 2 deals together
- [BioGeneration Ventures](https://shizune.co/investors/profile/biogeneration-ventures) — VC Fund, 1 deal together

## About Vesalius Biocapital Partners

VC Fund · Strassen, Luxembourg

Vesalius Biocapital Partners invests in companies active in human health through venture capital funds raised since 2007. They have contributed to developing 20 companies since inception.With more than € 150 million under management in two funds. Vesalius Biocapital Partners plays the role of lead investor in the large majority of its financingrounds.Their companies are based in Europe allowing easy interaction with management.They invest in all stages of development and do not shy away from relatively early-stage projects with a sound proprietary technology and corresponding IP, unique team skills and a clear competitive edge based on solid data.

5 contacts available at Vesalius Biocapital Partners.

| Name | Title | Profile |
| --- | --- | --- |
| Fei Tian | Analyst | https://shizune.co/investors/profile/fei-tian |
| Guy Geldhof | Partner | https://shizune.co/investors/profile/guy-geldhof |
| Stephane Verdood | Managing Partner | https://shizune.co/investors/profile/stephane-verdood |
| Alain Parthoens | Managing Partner | https://shizune.co/investors/profile/alain-parthoens |
| Christian Schneider | Managing Partner | https://shizune.co/investors/profile/christian-schneider |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Stephane Verdood invest in?

Stephane Verdood invests primarily in Health Care, Biotechnology and Pharmaceutical startups, most often at Series A and Series B stage. Most of the 8 investments tracked by Shizune back companies in The Netherlands. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Stephane Verdood last invest?

The most recent investment recorded for Stephane Verdood closed in Mar 2022. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co